Delfi Diagnostics Delfi-Tumor Fraction (Delfi-TF) Assay
Delfi Diagnostics announced the availability of its Delfi Tumor Fraction (Delfi-TF) fragmentome-based research-use-only (RUO) cancer monitoring assay for the noninvasive measurement of tumor burden and assessment of treatment response and resistance in patients with advanced cancer. The company said that the assay requires very little plasma, has a low cost of processing, and is not confounded by clonal hematopoiesis or driver mutation switches. Delfi also said it has entered a new research collaboration with Immunocore Holdings to evaluate the test as an early predictor of benefit from a novel class of bispecific T-cell receptor immunotherapies. The companies said Delfi's assay is highly correlated with the mutant allele fraction measures that are currently used to evaluate treatment response and resistance to immunotherapies in advanced cancer patients.